Replimune's Fate Hinges on Second FDA Review for Skin Cancer Drug

Investors in Replimune are bracing for a definitive verdict from U.S. regulators, with the company's stock reflecting the high-stakes uncertainty. The U.S. Food and Drug Administration is set to decide on the approval of RP1, a combination therapy for advanced melanoma, marking a critical second attempt after a surprising rejection last summer.

The memory of that July 2025 rejection, delivered via a Complete Response Letter, continues to weigh heavily on the market. The FDA's initial refusal cited concerns over the design of the IGNYTE clinical trial and questions about the proof of efficacy, particularly due to a heterogeneous patient population. Reports at the time suggested internal division within the agency, with support for the therapy reportedly overruled by a senior official's last-minute intervention. In response, Replimune submitted additional data and analyses in this new application to directly address those earlier reservations.

Trading activity in recent days has revealed palpable investor anxiety. On Thursday, share volume surged to approximately 3.13 million, nearly double the previous day's level, as the price saw a slight recovery to around $6.17. This followed a steep 15% sell-off on Wednesday. The technical picture remains weak, with the stock currently trading 20.7% below its 20-day moving average and deep in negative territory on a 100-day view. A Relative Strength Index (RSI) reading of 35.33 indicates the stock is nearing oversold conditions, underscoring the prevailing market skepticism.

The medical and commercial potential of RP1 is significant. A green light would make it one of the first HSV-1-based therapies for advanced melanoma patients who have not responded to prior immunotherapy treatments. The drug is designed to be used in combination with nivolumab, marketed as Opdivo. Sentiment among retail investors, tracked on platforms like Stocktwits, has recently cooled from optimistic to neutral as the binary nature of the risk becomes apparent.

Financially, Replimune holds cash reserves of $269.1 million, which management states is sufficient to fund operations into early 2027. The company currently generates no revenue, reports mounting losses, and is forecast to remain unprofitable for at least another three years. Despite these challenges and the regulatory hurdles, institutional investors have maintained a strong position, holding roughly 92.5% of the company's shares.

The immediate commercial future of the biotech firm rests on the April 10 decision. An approval would trigger the immediate launch of RP1 and unlock access to an additional $120 million from an existing credit facility. A second rejection, however, would force management to pivot its focus to other pipeline candidates like RP2 and could deal a severe blow to the entire clinical development timeline.

Ad

Replimune Stock: New Analysis - 10 April

Fresh Replimune information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Replimune analysis...